Home >> Research Area >>Metabolism>>HSP>> PU-WS13

PU-WS13

Grp94-specific Hsp90 inhibitor CAS# 1454619-14-7

PU-WS13

Catalog No. BCC6425----Order now to get a substantial discount!

Product Name & Size Price Stock
PU-WS13: 5mg $104 In Stock
PU-WS13: 10mg Please Inquire In Stock
PU-WS13: 20mg Please Inquire Please Inquire
PU-WS13: 50mg Please Inquire Please Inquire
PU-WS13: 100mg Please Inquire Please Inquire
PU-WS13: 200mg Please Inquire Please Inquire
PU-WS13: 500mg Please Inquire Please Inquire
PU-WS13: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of PU-WS13

Number of papers citing our products

Chemical structure

PU-WS13

3D structure

Chemical Properties of PU-WS13

Cas No. 1454619-14-7 SDF Download SDF
PubChem ID 71660551 Appearance Powder
Formula C17H20Cl2N6S M.Wt 411.35
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 40 mg/mL (97.24 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 8-(3,5-dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine
SMILES CC(C)NCCCN1C2=C(C(=NC=N2)N)N=C1SC3=CC(=CC(=C3)Cl)Cl
Standard InChIKey JYSLFQTWNRYWJT-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H20Cl2N6S/c1-10(2)21-4-3-5-25-16-14(15(20)22-9-23-16)24-17(25)26-13-7-11(18)6-12(19)8-13/h6-10,21H,3-5H2,1-2H3,(H2,20,22,23)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of PU-WS13

DescriptionPU-WS13 is a selective Grp94 inhibitor, with an EC50 of 0.22 μM.In Vitro:PU-WS13 is a Grp94 inhibitor, with an EC50 of 0.22 μM. PU-WS13 also slightly suppresses Hsp90α, Hsp90β and Trap-1, with EC50s of 27.3, 41.8 and 7.3 μM, respectively. PU-WS13 (2.5-20 μM) shows no toxicity on two nonmalignant cell lines. PU-WS13 (15 μM) disrupts the circular architecture of HER2 at the plasma membrane of SKBr3 cells mediated through Grp94. PU-WS13 inhibits Grp94, and the inhibition induces apoptosis in and reduce the viability of HER2 overexpressing breast cancer cells[1].

References:
[1]. Patel PD, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013 Nov;9(11):677-684.

Protocol

Kinase Assay [1]
The Hsp90 FP competition assays are carried out in black 96-well micro-plates in a total volume of 100 μL in each well. A stock of 10 μM cy3B-GM and PU-FITC3 is prepared in DMSO and diluted with Felts buffer (20 mM Hepes (K), pH 7.3, 50 mM KCl, 2 mM DTT, 5 mM MgCl2, 20 mM Na2MoO4 and 0.01% NP40 with 0.1 mg/mL BGG). To each well is added the fluorescent dye-labeled Hsp90 ligand (6 nM cy3B-GM for Hsp90α, Hsp90β and Grp94 and 3 nM PU-FITC3 for Trap-1), protein (10 nM Hsp90α, 10 nM Hsp90β, 10 nM Grp94, 30 nM Trap-1) and tested inhibitor (including PU-WS13, initial stock in DMSO) in a final volume of 100 μL Felts buffer. Compounds are added in duplicate or triplicate wells. For each assay, background wells (buffer only), tracer controls (free, fluorescent dye-labeled Hsp90 ligand only) and bound controls (fluorescent dye-labeled Hsp90 ligand in the presence of protein) are included on each assay plate. The assay plate is incubated on a shaker at 4°C for 24 h, and the FP values (in mP) are measured. The fraction of fluorescent dye-labeled Hsp90 ligand bound to Hsp90 is correlated to the mP value and plotted against values of competitor concentrations. The inhibitor concentration at which 50% of bound fluorescent dye-labeled Hsp90 ligand is displaced is obtained by fitting the data. For cy3B-GM, an excitation filter at 530 nm and an emission filter at 580 nm are used with a dichroic mirror of 561 nm. For PU-FITC3, an excitation filter at 485 nm and an emission filter at 530 nm are used with a dichroic mirror of 505 nm. All of the experimental data are analyzed, and binding affinity values are given as relative binding affinity values (EC50, concentration at which 50% of fluorescent ligand is competed off by compound)[1].

Cell Assay [1]
Cells are treated for 72 h with inhibitors (including PU-WS13) or transfected with Grp94 siRNA or control siRNA, and their viability is assessed using CellTiter-Glo luminescent Cell Viability Assay. The method determines the number of viable cells in culture based on quantification of the ATP present, which signals the presence of metabolically active cells[1].

References:
[1]. Patel PD, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013 Nov;9(11):677-684.

PU-WS13 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

PU-WS13 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of PU-WS13

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.431 mL 12.1551 mL 24.3102 mL 48.6204 mL 60.7755 mL
5 mM 0.4862 mL 2.431 mL 4.862 mL 9.7241 mL 12.1551 mL
10 mM 0.2431 mL 1.2155 mL 2.431 mL 4.862 mL 6.0775 mL
50 mM 0.0486 mL 0.2431 mL 0.4862 mL 0.9724 mL 1.2155 mL
100 mM 0.0243 mL 0.1216 mL 0.2431 mL 0.4862 mL 0.6078 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on PU-WS13

The Hsp90 family of molecular chaperones regulates and maintains cell homeostasis under proteotoxic stress and pathogenic pressure. In humans, Hsp90α and Hsp90β in the cytoplasm, Grp94 in the endoplasmic reticulum and Trap-1 in the mitochondria are the four Hsp90 paralogs. PU-WS13 is a potent, Grp94-specific Hsp90 inhibitor of the purine scaffold class.

In vitro: Brief treatment of SKBr3 cells with PU-WS13 disrupted the circular architecture of HER2 at the plasma membrane, resulting in a ‘shredded’ HER2 pattern. The effect of PU-WS13 on the HER2 surface architecture is mediated through Grp94. Upon treatment of cells with PU-WS13, a rapid accumulation of cells in the sub-G1 phase, PARP cleavage and a substantial increase in markers of early- and late-stage apoptosis were noted [1].

In vivo: Potent and durable anti-tumor effects in TNBC xenografts, including complete response and tumor regression, without toxicity to the host are achieved with PUH71, a chemical analogue of PU-WS13. Notably, TNBC tumors respond to retreatment with PUH71 for several cycles extending for over 5 months without evidence of resistance or toxicity [2].

Clinical trial: Up to now, PU-WS13 is still in the preclinical development stage.

Reference:
[1] Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013 Nov;9(11):677-84.
[2] Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73.

Featured Products
New Products
 

Description

PU-WS13 is a selective Grp94 inhibitor, with an EC50 of 0.22 μM.

Keywords:

PU-WS13,1454619-14-7,Natural Products,HSP, buy PU-WS13 , PU-WS13 supplier , purchase PU-WS13 , PU-WS13 cost , PU-WS13 manufacturer , order PU-WS13 , high purity PU-WS13

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: